Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNP520 for Prevention of Alzheimer's Disease Onset
CTR20190062Phase 3Suspended
- Sponsor
- Novartis
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of umibecestat in Alzheimer's disease (AD), mild cognitive impairment due to Alzheimer's disease, sponsored by Novartis. Started Apr 2019; status: suspended.
02
Drugs
umibecestat
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on CTR20190062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190062.